Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.
Stock data | 2024 | Change |
---|---|---|
Price | $0.0036503012922097493 | N/A |
Market Cap | $484.15K | N/A |
Shares Outstanding | 132.63M | N/A |
Employees | 12.00 | N/A |